Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) plays a key role in treatment of hematological malignancies. However, relapse of hematological malignancies is the main challenge of HSCT that causes significant declination of overall survival (OS) after HSCT. In recent years, the newly emerging chimeric antigen receptor T-cell (CAR-T) immunotherapy has obtained remarkable achievements in hematological malignancies, and with the progress of research, the safety and effectiveness of CAR-T are also increasing. Studies have found that donor-derived CAR-T can significantly increase OS rates in relapsed patients after transplantation through and control disease recurrence and progression. This review will focus on the efficacy and safety of donor-derived CAR-T in relapsed hematological malignancies after allo-HSCT, and summarize the main challenges to be resolved. Key words: Hematologic neoplasms; Hematopoietic stem cell transplantation; Recurrence; Donor-derived; Chimeric antigen receptor T-cell
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
